Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant vemurafenib, cobimetinib, and atezolizumab for high-risk resectable melanoma
2024-516659-41-00Phase 2Authorised
- Sponsor
- Fondazione Melanoma Onlus
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vemurafenib, cobimetinib and atezolizumab in cutaneous melanoma (CM), sponsored by Fondazione Melanoma Onlus. Primary endpoint: Pathologic complete response rate. Planned start Oct 2020; status: authorised.
02
Drugs
vemurafenibcobimetinibatezolizumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2024-516659-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516659-41-00.